These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8405534)

  • 1. Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion, and pregnancy in a World Health Organization group II anovulatory woman.
    Hornnes P; Giroud D; Howles C; Loumaye E
    Fertil Steril; 1993 Oct; 60(4):724-6. PubMed ID: 8405534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility.
    Balen AH; Mulders AG; Fauser BC; Schoot BC; Renier MA; Devroey P; Struijs MJ; Mannaerts BM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6297-304. PubMed ID: 15579793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women and WHO group II anovulatory infertile patients.
    Balasch J; Fábregues F; Peñarrubia J; Creus M; Vidal R; Casamitjana R; Manau D; Vanrell JA
    J Assist Reprod Genet; 1998 Oct; 15(9):552-9. PubMed ID: 9822984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study.
    Hugues JN; Soussis J; Calderon I; Balasch J; Anderson RA; Romeu A;
    Hum Reprod; 2005 Mar; 20(3):629-35. PubMed ID: 15618252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain.
    Burgués S;
    Hum Reprod; 2001 Dec; 16(12):2525-32. PubMed ID: 11726569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG.
    International Recombinant Human Chorionic Gonadotropin Study Group
    Fertil Steril; 2001 Jun; 75(6):1111-8. PubMed ID: 11384635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome.
    Catteau-Jonard S; Pigny P; Reyss AC; Decanter C; Poncelet E; Dewailly D
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4138-43. PubMed ID: 17698904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens.
    Balasch J; Fábregues F; Creus M; Puerto B; Peñarrubia J; Vanrell JA
    Hum Reprod; 2001 Apr; 16(4):652-6. PubMed ID: 11278212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group.
    J Clin Endocrinol Metab; 1998 May; 83(5):1507-14. PubMed ID: 9589647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial.
    Calaf Alsina J; Ruiz Balda JA; Romeu Sarrió A; Caballero Fernández V; Cano Trigo I; Gómez Parga JL; González Batres C; Rodríguez Escudero FJ
    BJOG; 2003 Dec; 110(12):1072-7. PubMed ID: 14664878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of ovulation in polycystic ovary: human menopausal gonadotropin or human urinary follicle stimulating hormone?
    Venturoli S; Paradisi R; Fabbri R; Porcu E; Orsini LF; Flamigni C
    Int J Fertil; 1987; 32(1):66-70. PubMed ID: 2880819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of persistent anovulation in polycystic ovarian disease by administration of chronic low-dose follicle-stimulating hormone.
    Kamrava MM; Seibel MM; Berger MJ; Thompson I; Taymor ML
    Fertil Steril; 1982 Apr; 37(4):520-3. PubMed ID: 6802679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome.
    Homburg R; Levy T; Ben-Rafael Z
    Fertil Steril; 1995 Apr; 63(4):729-33. PubMed ID: 7890055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
    Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
    J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group.
    Coelingh Bennink HJ; Fauser BC; Out HJ
    Fertil Steril; 1998 Jan; 69(1):19-25. PubMed ID: 9457926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment.
    Fulghesu AM; Apa R; Belosi C; Ciampelli M; Selvaggi L; Cucinelli F; Caruso A; Mancuso S; Lanzone A
    Horm Res; 2001; 55(5):224-8. PubMed ID: 11740143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human FSH (rhFSH), urinary purified FSH (uFSH), and hMG on small preantral follicles and tertiary follicles from normal adult and androgen-sterilized female mice.
    Liu X; Andoh K; Mizunuma H; Kamijo T; Kikuchi N; Yamada K; Ibuki Y
    Fertil Steril; 2000 Feb; 73(2):372-80. PubMed ID: 10685546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation.
    Loumaye E; Engrand P; Shoham Z; Hillier SG; Baird DT
    Hum Reprod; 2003 Feb; 18(2):314-22. PubMed ID: 12571167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility.
    Balen AH; Platteau P; Andersen AN; Devroey P; Sørensen P; Helmgaard L; Arce JC
    BJOG; 2006 Oct; 113(10):1195-202. PubMed ID: 16903840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.